Further study is warranted to determine whether these differences for S-1 versus capecitabine are reproduced in combination with oxaliplatin and immune checkpoint inhibitors, the new standard of care for HER2-negative unresectable advanced or recurrent gastric cancer. The gene discussed is ERBB2; the disease is gastric cancer.